Abstract
The majority of patients with head and neck cancer present with locoregionally advanced disease (1–3). For most of these patients, standard therapy consists of surgery followed by radiotherapy, unless the patient has unresectable disease due to the specific anatomic location (e.g. nasopharynx) or widespread involvement of neighboring structures, or is medically inoperable. In these cases, standard therapy consists of radiotherapy alone. However, less than 30% of patients are cured and locoregional disease persistence/ recurrence is the most common pattern of failure. Distant metastases, second malignancies, and medical problems related to smoking and alcohol consumption are significant additional causes of treatment failure and death (4,5). Chemotherapy has traditionally been investigated in patients with recurrent or metastatic disease (1–3). In that setting, response rates of 30% with a median response duration of 3 months are usually achieved. Commonly used regimens include single agent methotrexate or cisplatin, and the combination of cisplatin and a 4 to 5 day continuous infusion of fluorouracil. The latter combination, in particular, has been frequently investigated with response rates ranging from 20% to 74% (6).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Vokes, E.E., 1992, Head and neck cancer, In: Perry MC, ed. Chemotherapy Source Book. Baltimore: Williams and Wilkins, 918.
Hong, W.K. and Bromer, R., 1983, Current Concepts: Chemotherapy in head and neck cancer, N Engl J Med 308: 75.
Clark, J.R. and Frei, E. III, 1989, Chemotherapy for head and neck cancer: Progress and controversy in the management of patients with M0 disease, Sem Oncol 16 (Suppl 6): 44.
Cooper, J.S., Pajak, T.F., Rubin, P., et al, 1989, Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience, Int J Radiat Oncol Biol Phys 17: 449.
Hong, W.K., Lippman, S.M., Itri, L.M., et al, 1990, Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck, N Engl J Med 323: 795.
Urba, S.G. and Forastiere, A.A, 1989, Systemic therapy of head and neck cancer: Most effective agents, areas of promise, Oncology 3: 79.
Vokes, E.E., Awan, A.M., and Weichselbaum, R.R., 1991, Radiotherapy with concomitant chemotherapy for head and neck cancer, Hematol/Oncol Clin North Am 5: 753.
Jacobs, C. and Makuch, R., 1990, Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the head and neck contracts program, J Clin Oncol 8: 838.
Schuller, D.E., Metch, B., Mattox, D., et al, 1988, Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group, Laryngoscope 98: 1205.
The Department of Veterans Affairs Laryngeal Cancer Study Group, 1991, Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer, N Engl J Med 324: 1685.
Laramore, G.E., Scott, C.B., Al-Sarraf, M., et al, 1992, Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034, Ira J Radiat Oncol Biol Phys 23: 705.
Rooney, M., Kish, J., Jacobs, J., et al, 1985, Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin, Cancer 55: 1123.
Ervin, T.J., Clark, J.R., Weichselbaum, R.R., et al, 1987, An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck, J Clin Oncol 5: 10.
Spaulding, M.B., Lore, J.M., Sundquist, N., 1989, Long-term follow-up of chemotherapy in advanced head and neck cancer, Arch Otolaryngol Head Neck Surg, 115: 68.
Vokes, E.E., Mick, R., Lester, E.P., et al, 1991, Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution, J Clin Oncol 9: 1376.
Ensley, J., Jacobs, J., Weaver, A., et al, 1984, Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck, Cancer, 54: 811.
Vokes, E.E. and Weichselbaum, R.R., 1990, Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors, J Clin Oncol 8: 911.
Lo, T.C., Wiley, A.L. Jr., Ansfield, F.J., et al, 1976, Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: A randomized study, Am J Roentgenol 126: 229.
Browman, G.P., Archibald, S.D., Young, J.E.M., et al, 1983, Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer, J Clin Oncol 12: 787.
Browman, G.P., Levine, M.N., Goodyear, M.D., et al, 1988, Methotrexate/fluorouracü scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: Results from a randomized trial, J Clin Oncol 6: 963.
Lindelov, B., Hansen, H.S., 1989, The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer, Acta Oncol 28 (2): 227.
Browman, G.P., Goodyear, M.D.E., Levine, M.N., et al, 1990, Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: A randomized placebo-controlled clinical trial, J Clin Oncol 8: 203.
Ackland, S.P. and Schilsky, R.L., 1987, High-dose methotrexate: A critical reappraisal, J Clin Oncol 5: 2017.
Sironak, F.M., DeGraw, J.I., Schmid, F.A., et al, 1984, New folate analogs of the 10-Deaza-Aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine models, Cancer Chemother Pharmacol 12: 26.
Moccio, D.M., Sironak, F.M., Samuels, L.L., et al, 1984, Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells. A clinically directed laboratory study, Cancer Res 44: 352.
Braakhuis, B.J., van Dongen, G.A., Bagnay, M., et al, 1989, Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice, Head-Neck 11 (6): 511.
Brown, D.H., Braakhuis, B.J., van Dongen, G.A., et al, 1989, Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts, Anticancer Res 9 (6): 1549.
Schomagel, J.H., Verweij, J., Cognetti, F., et al, for the EORTC Head and Neck Cancer Cooperative Group, 1991, A randomized phase HI trial of methotrexate vs 10-ethyl-10-deaza-aminopterin in patients with advanced and/or metastatic squamous cell carcinoma of the head and neck, Eur J Cancer 27 (2): 138 (Abstract #825).
Schornagel, J.H., Verweij, J,., de Mulder, P.H.M. et al, 1992, A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced or/or recurrent squamous cell carcinoma of the head and neck, Ann Oncol 3: 223.
Robert, F., 1988, Trimetrexate as a single agent in patients with advanced head and neck cancer, Semin Oncol 15 (2): 22.
Duch, D.S., Edelstein, M.P., Bowers, S.W., Nichol, C.A., 1982, Biochemical and chemotherapeutic studies on 2,4-diamino-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d] pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase, Cancer Res 42: 3987.
Sedwick, W.D., Hamrell, M., Brown, O.E., Laszlo, J., 1982, Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d] pyrimidine (BW301U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines. Mol Pharmacol 22: 766.
Taylor, I.W., Slowiaczek, P., Friedlander, M.L., et al, 1985, Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake, Cancer Res 45: 978.
Uen, W.-C., Huang, A.T., Mennel, R., et al, 1992, A phase H study of piritrexim in patients with advanced squamous head and neck cancer, Cancer 69: 1008.
Vokes, E.E., Dimery, I.W., Jacobs, C.D., et al, 1991, A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer, Cancer 67: 2253.
Vokes, E.E., Moran, W.J., Mick, R., et al, 1989, Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer, J Clin Oncol 7: 838.
Vokes, E.E., Panje, W.R., Mick, R., et al, 1990, A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer, Cancer 66: 206.
Vokes, E.E., Haraf, D.J., Panje, W.R., et al, 1992, Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer, Semin Oncol 19 (9): 53.
Kinsella, T.J., 1992, Radiosensitization and cell kinetics: Clinical implications for S-phase-specific radiosensitizers, Semin Oncol 19 (9): 41.
Kinsella, T.J., 1992, Radiosensitization and cell kinetics: Clinical implications for S-phase-specific radiosensitizers, Semin Oncol 19 (9): 41.
Moran, R.G., Danenberg, P.V., Heidelberger, C., 1982, Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem Pharmacol 31: 2929.
Schilsky, R.L., Ratain, M.J., Vokes, E.E., et al, 1992, Laboratory and clinical studies of biochemical modulation by hydroxyurea, Semin Oncol 19 (9): 84.
Byfield, J.E., Sharp, T.R., Frankel, S.S., et al, 1984, Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck, J Clin Oncol 2: 406.
Vokes, E.E., Panje, W.R., Schilsky, R.L., et al, 1989, Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: A phase I-II study, J Clin Oncol 7: 761.
Haraf, D.J., Vokes, E.E., Panje, W.R., et al, 1991, Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer, Am J Clin Oncol 14 (5): 419.
Haraf, D.J., Vokes, E.E., Panje, W.R., et al, 1991, Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer, Am J Clin Oncol 14 (5): 419.
Weppelman, B., Wheeler, R.H., Peters, G.E., et al, 1992, Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation, Int J Radiat Oncol Biol Phys 22: 1051.
Greenberg, B., Ahmann, F., Garewal, H., et al, 1987, Neoadjuvant therapy for advanced head and neck cancer with allopurinol-mpdulated high dose 5-fluorouracil and cisplatin: A phase I-II study, Cancer 59: 1860.
Loprinzi, C.L., Cianflone, S.G., Dose, A.M., et al, 1990, A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis, Cancer 65 (8): 1879.
Vokes, E.E., Choi, K.E., Schilsky, R.L., et al, 1988, Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer, J Clin Oncol 6: 618.
Straw, J.A., Szapary, D., Wynn, W.T., 1984, Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects, Cancer Res 44: 3114.
Vokes, E.E., Schilsky, R.L., Weichselbaum, R.R., et al, 1990, Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacologic analysis, J Clin Oncol 8: 241.
Vokes, E.E., Weichselbaum, R.R., Mick, R., et al, 1992, Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer, J Natl Cancer Inst 84: 877.
Dreyfuss, A.I., Clark, J.R., Wright, J.E., et al, 1990 Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck, Ann Int Med 112: 167.
Loeffler, T.M., Lindemann, J., Luckhaupt, H., et al, 1988, Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with splitdose cisplatinum, 5-fluorouracil and leucovorin, Adv Exp Med Biol 244: 267.
Merlano, M., Bacigalupo, A., Benasso, M., et al, 1990, 5-fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer, Am J Clin Oncol 13 (1): 1.
Jacobs, C., Lyman G., Velez-Garcia, E., et al, 1992, A phase HI randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck, J Clin Oncol 10: 257.
Wendt, T.G., Hartenstein, R.C., Wustrow, T.P.U., and Lissner, J., 1989, Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: A phase II study, J Clin Oncol 7: 471.
Vokes, E.E., Haraf, D.J., McEvilly, J.-M., et, 1992, Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach, Ann Oncol 3: 79.
Vokes, E.E., Ratain, M.J., Mick, R., et al, 1992, A clinical and pharmacologic phase I-II study of PFL with interferon alfa-2B for head and neck cancer, Proc Am Soc Clin Oncol 11: 243 (Abstract #782).
Bensmaine, A., Azli, N., Soulie, P., et al, 1992, CDDP-5FU Modulation by alpha IFN2B in metastatic and or recurrent head and neck squamous cell carcinoma, Proc AACR 33: 223 (Abstract #1338).
Santini, J., Milano, G., Thyss, A., et al, 1989, 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer, Br J Cancer 59: 287.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vokes, E.E. (1993). Fluorouracil Modulation in Head and Neck Cancer. In: Rustum, Y.M. (eds) Novel Approaches to Selective Treatments of Human Solid Tumors. Advances in Experimental Medicine and Biology, vol 339. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2488-5_20
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2488-5_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6060-5
Online ISBN: 978-1-4615-2488-5
eBook Packages: Springer Book Archive